Technologies related to NIAID

Custom text
Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus
Ref: TAB-3448 | Updated: 06/21/2021
Human Monoclonal Antibodies Targeting SARS-CoV-2
Ref: E-030-2021-0 | Updated: 06/21/2021
Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants
Ref: TAB-3446 | Updated: 06/04/2021
Antibodies Targeting The Spike Protein Of Coronaviruses
Ref: E-037-2021-0 | Updated: 06/04/2021
Novel Monoclonal Antibodies To Ebolavirus Glycoprotein
Ref: E-045-2015-0 | Updated: 06/08/2021
Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection
Ref: TAB-3130 | Updated: 06/04/2021
Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use
Ref: TAB-3439 | Updated: 06/04/2021
Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes As A Single Dose COVID-19 Vaccine
Ref: E-068-2021-0 | Updated: 06/04/2021
Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene
Ref: TAB-3437 | Updated: 06/04/2021
Improved Live-attenuated Vaccine For Respiratory Syncytial Virus (RSV) Bearing Codonpair Deoptimized NS1, NS2, N, P, M And SH Genes And Additional Point Mutations In The P gene
Ref: E-104-2020-0 | Updated: 06/04/2021
Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use
Ref: TAB-3434 | Updated: 06/04/2021
Replication-Competent Adenovirus Type 4-SARS-CoV-2 Vaccines And Their Use
Ref: E-055-2021-0 | Updated: 06/04/2021
Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells
Ref: TAB-3431 | Updated: 06/04/2021
Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection Of B Cells
Ref: E-020-2020-0 | Updated: 06/04/2021
Norovirus Specific Nanobodies For Diagnostic And Therapeutic
Ref: E-136-2013-0 | Updated: 06/08/2021
Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use
Ref: TAB-3106 | Updated: 06/04/2021
A VSV-EBOV-Based Vaccine Against COVID-19
Ref: TAB-3430 | Updated: 06/04/2021
A VSV-EBOV-based Vaccine Against COVID-19
Ref: E-258-2020-0 | Updated: 06/04/2021
Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus
Ref: TAB-3429 | Updated: 06/04/2021
Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus
Ref: E-131-2019-0 | Updated: 06/04/2021
Hybridoma cell lines producing antibodies to RSV NS1
Ref: TAB-3339 | Updated: 06/04/2021
Hybridoma Cell Lines Producing Antibodies To RSV NS1 And The Imonoclonal Antibodies Against RSV NS1
Ref: E-167-2018-0 | Updated: 06/04/2021
Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2
Ref: TAB-641 | Updated: 06/04/2021
Stem Cell Factor-Responsive FC&RI Bearing Human Mast Cell Line LAD2
Ref: E-279-2001-0 | Updated: 06/08/2021
Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection
Ref: TAB-3424 | Updated: 06/04/2021
Identification Of A New Human Monoclonal Antibody That More Potently Prevents Malaria Infection
Ref: E-087-2019-0 | Updated: 06/04/2021
Recombinant Prefusion Measles and Mumps F and F–HN (H) Glycoproteins for Vaccine Development
Ref: TAB-3409 | Updated: 06/04/2021
Recombinant Prefusion Measles And Mumps F And F-HN Glycoproteins And Their Use
Ref: E-153-2019-0 | Updated: 06/04/2021
Structure-Based Design of SARS-CoV-2 Spike Immunogens Stabilized in the RBD-All Down Conformation
Ref: TAB-3420 | Updated: 06/04/2021
Structure-Based Design Of Conformationally-Stabilized SARS-CoV-2 Spike Immunogens
Ref: E-187-2020-0 | Updated: 06/04/2021
Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine
Ref: TAB-2463 | Updated: 06/04/2021
Development Of Self-Assembling Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine
Ref: E-293-2011-0 | Updated: 06/08/2021
Development Of Self-Assembling Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine
Ref: E-293-2011-1 | Updated: 06/08/2021
Development Of Self-Assembling Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine
Ref: E-293-2011-2 | Updated: 06/08/2021
Monoclonal Antibodies that Neutralize B. anthracis Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)
Ref: TAB-1580 | Updated: 06/04/2021
Protein Nanoparticles for Antigen Display in Vaccines
Ref: TAB-3254 | Updated: 06/21/2021
Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications
Ref: TAB-519 | Updated: 06/04/2021
Chimpanzee/Human Chimeric Monoclonal Antibodies That React With The Capsule Of Bacillus Anthracis And Kill The Organism By Opsonophagocytosis.
Ref: E-125-2008-0 | Updated: 06/08/2021
Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences
Ref: TAB-3346 | Updated: 06/21/2021
Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination
Ref: TAB-538 | Updated: 06/04/2021
Infectious cDNA Clone of GB Virus B and Uses Thereof
Ref: E-173-1999-0 | Updated: 06/08/2021
Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses
Ref: TAB-3388 | Updated: 06/21/2021
Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus
Ref: TAB-560 | Updated: 06/04/2021
Recombinant proteins of the swine hepatitis E virus and their uses as a vaccine and diagnostic reagents for medical and veterinary applns.
Ref: E-304-1998-0 | Updated: 06/08/2021
A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics
Ref: TAB-1501 | Updated: 06/04/2021
A Varicella-zoster Virus Mutant That Is Markedly Impaired For Latent Infection
Ref: E-029-2007-0 | Updated: 06/04/2021
Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of.....
Ref: E-043-2000-0 | Updated: 06/08/2021
Monoclonal Antibodies Against Orthopoxviruses
Ref: TAB-1601 | Updated: 06/04/2021
Monoclonal Antibodies Against Orthopoxviruses
Ref: E-145-2004-3 | Updated: 06/04/2021
Anti-hepatitis A Virus Antibodies
Ref: E-356-2001-0 | Updated: 06/08/2021
Monoclonal Antibodies that Neutralize Norovirus
Ref: TAB-2636 | Updated: 06/04/2021
Cloned Genomes of Infectious Hepatitis C Viruses and Uses Thereof
Ref: E-050-1998-0 | Updated: 06/04/2021
Development Of A Polyvalent Viral Like Particle Vaccine To Provide Broad Protection Against Influenza A Viruses Of Different Subtypes
Ref: E-195-2014-0 | Updated: 06/21/2021
Monoclonal Antibodies Against Bacillus Anthracis Antigens
Ref: TAB-3404 | Updated: 06/04/2021
Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof
Ref: E-100-1999-0 | Updated: 06/04/2021
Protein Nanoparticles For Antigen Display
Ref: E-005-2017-0 | Updated: 06/21/2021
Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof
Ref: TAB-347 | Updated: 06/04/2021
HCV/BVDV Chimeric Genomes and Uses Thereof
Ref: E-102-1999-0 | Updated: 06/04/2021
Universal Influenza Virus Probes For Enrichment Of Influenza Viral Sequences
Ref: E-032-2018-0 | Updated: 06/21/2021
Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof
Ref: TAB-488 | Updated: 06/04/2021
Chimpanzee/Human Chimeric Monoclonal Antibodies That Neutralize Norwalk Virus
Ref: E-226-2011-0 | Updated: 06/08/2021
Development Of A Broadly Protective Influenza Vaccine Consisting Of A Cocktail Of Inactivated Avian Influenza Viruses 1
Ref: E-033-2018-0 | Updated: 06/21/2021
HCV/BVDV Chimeric Genomes and Uses Thereof
Ref: TAB-489 | Updated: 06/04/2021
Chimpaneze Monoclonal Antibody That Neutralizes Anthrax Protective Antigen (PA) Toxin
Ref: E-146-2004-0 | Updated: 06/08/2021
Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
Ref: TAB-3081 | Updated: 06/21/2021
Infectious cDNA Clone of GB Virus B and Uses Thereof
Ref: TAB-490 | Updated: 06/04/2021
Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin
Ref: E-123-2007-0 | Updated: 06/08/2021
Middle East Respiratory Syndrome Coronavirus Antibodies
Ref: TAB-3344 | Updated: 06/04/2021
Novel Vaccines And Monoclonal Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Ref: E-239-2014-0 | Updated: 06/08/2021
Highly Sensitive Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein
Ref: E-109-2007-1 | Updated: 06/08/2021
Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay for the Detection of Alpha-Synuclein Seeding Activity Associated with Synucleinopathies
Ref: TAB-3406 | Updated: 06/04/2021
A Rapid Ultrasensitive Assay for Detecting Prions Based on the Seeded Polymerization of Recombinant Normal Prion Protein (rPrP-sen)
Ref: TAB-3407 | Updated: 06/04/2021
Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay For The Detection Of Alpha-Synuclein Seeding Activity Associated With Synucleinopathies
Ref: E-233-2017-0 | Updated: 06/04/2021
Highly Sensitive Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein
Ref: E-109-2007-0 | Updated: 06/08/2021
Use of the Intracellular Signaling Domain of Receptor CD28H as a Component of Chimeric Antigen Receptors to Overcome Inhibition of Cytotoxic Lymphocytes by Checkpoint Receptors
Ref: TAB-3408 | Updated: 06/04/2021
Use Of Receptor CD28H As A Component Of Chimeric Antigen Receptors In Lymphocytes For Cancer Immunotherapy
Ref: E-097-2020-0 | Updated: 06/04/2021
Prefusion Coronavirus Spike Proteins and Their Use
Ref: TAB-3261 | Updated: 06/04/2021
Stabilized Coronavirus Proteins For Vaccination
Ref: E-234-2016-0 | Updated: 06/08/2021
Stabilized Coronavirus Proteins For Vaccination
Ref: E-234-2016-1 | Updated: 06/08/2021
Establishment Of Continuous Cell Lines Persistently Expressing Native HIV-1 Envelope Trimers
Ref: E-185-2018-0 | Updated: 06/08/2021
Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane
Ref: TAB-3370 | Updated: 06/04/2021
Improvement of Broadly HIV-Neutralizing Antibodies; Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV Infection
Ref: TAB-3386 | Updated: 06/04/2021
Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof
Ref: TAB-3393 | Updated: 06/04/2021
Improvement Of Broadly HIV-neutralizing Antibodies
Ref: E-034-2018-0 | Updated: 06/04/2021
Ebola Antibodies From Human Vaccinee
Ref: E-061-2018-0 | Updated: 06/04/2021
A High-Yield Perfusion-Based Transient Gene Expression Bioprocess
Ref: TAB-3387 | Updated: 06/04/2021
Development Of A High-yield Perfusion-based Transient Gene Expression (TGE) Bioprocess For Universal Influenza Vaccine
Ref: E-187-2018-0 | Updated: 06/08/2021
Floxed Targeted Mouse Strain for Use in Conditional Deletion of the Irf8 Gene
Ref: TAB-3383 | Updated: 06/04/2021
Development Of A Mouse Strain For Use In Conditional Deletion Of The Irf8 Gene
Ref: E-062-2012-0 | Updated: 06/04/2021
Recombinant Nipah F Proteins and Their Use
Ref: TAB-3382 | Updated: 06/04/2021
Recombinant Nipah F Proteins And Their Use
Ref: E-050-2018-0 | Updated: 06/04/2021
Recombinant HIV-1 Envelope Proteins and Their Use
Ref: TAB-3350 | Updated: 06/04/2021
Structure-based Design Of Soluble Immunogens That Mimic The Prefusion-closed Conformation Of The HIV-1 Viral Spike
Ref: E-240-2017-0 | Updated: 06/08/2021
Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8
Ref: TAB-3347 | Updated: 06/04/2021
Optimized Variants Of Antibody 10E8 And Their Use (variants 1, 4, 5)
Ref: E-133-2015-0 | Updated: 06/08/2021
Methods for Dagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level.
Ref: TAB-3343 | Updated: 06/04/2021
Targeting The CD153/CD30 Pathway For The Treatment And Diagnosis Of Tuberculosis
Ref: E-085-2018-0 | Updated: 06/08/2021
Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection
Ref: TAB-3345 | Updated: 06/04/2021
Potent Neutralizing Antibodies Against Epstein-Barr Virus And Their Use
Ref: E-001-2017-0 | Updated: 06/08/2021
Epstein-Barr Virus Antibodies That Neutralize Virus Infection In Both Epithelial Cells And B Cells And Inhibit Fusion
Ref: E-079-2018-0 | Updated: 06/08/2021

Pages

Subscribe to Technologies related to NIAID